Collectively, cotreatment using ATR inhibitors and PARPi revealed evidence of synthetic lethality in many types of tumor cells, and previous explorations have undoubtedly paved the way for further investigation into the spectrum of PARP-inhibitor-resistant cells. The gene discussed is PARP1; the disease is neoplasm.